<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NEOMYCIN SULFATE</span><br/>(nee-oh-mye'sin)<br/><span class="topboxtradename">Mycifradin, </span><span class="topboxtradename">Myciguent, </span><span class="topboxtradename">Neo-Tabs, </span><span class="topboxtradename">Neo-fradin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">aminoglycoside antibiotic</span><br/><b>Prototype: </b>Gentamicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablet; 125 mg/5 mL oral solution; 3.5 mg/g ointment, cream</p>
<h1><a name="action">Actions</a></h1>
<p>Aminoglycoside antibiotic obtained from <i>Streptomyces fradiae;</i> reported to be the most potent in neuromuscular blocking action and the most toxic of this group.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against a wide variety of gram-negative bacteria, including <i>Citrobacter, Escherichia coli, Enterobacter, Klebsiella,</i> <i>Proteus</i> (including indole-positive and indole-negative strains), <i>Pseudomonas aeruginosa,</i> and <i>Serratia sp.</i> Also effective against certain gram-positive organisms, particularly, penicillin-sensitive and some methicillin-resistant
         strains of <i>Staphylococcus aureus</i> (MRSA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Severe diarrhea caused by enteropathogenic <i>Escherichia coli;</i> preoperative intestinal antisepsis; to inhibit nitrogen-forming bacteria of GI tract in patients with cirrhosis or hepatic
         coma and for urinary tract infections caused by susceptible organisms. Also topically for short-term treatment of eye, ear,
         and skin infections. Available in a variety of creams, ointments, and sprays in combination with other antibiotics and corticosteroids.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use of oral drug in patients with intestinal obstruction; ulcerative bowel lesions; topical applications over large skin areas;
         parenteral use in patients with kidney disease or impaired hearing; parkinsonism; myasthenia gravis; pregnancy (category D),
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Topical otic applications in patients with perforated eardrum, children.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Intestinal Antisepsis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g q1h times 4 doses, then 1 g q4h times 5 doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10.3 mg/kg q46h for 3 d<br/><br/><span class="indicationtitle">Hepatic Coma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 412 g/d in 4 divided doses for 56 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 437.51225 mg/m<sup>2</sup> q6h for 56 d<br/><br/><span class="indicationtitle">Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg/kg in 4 divided doses for 23 d <span class="rdroute">IM</span> 1.32.6 mg/kg q6h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 8.75 mg/kg q6h for 23 d<br/><br/><span class="indicationtitle">Cutaneous Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply 13 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Preoperative bowel preparation: Saline laxative is generally given immediately before neomycin therapy is initiated.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Consult physician about what to use for cleansing skin before each application.</li>
<li>Make sure ear canal is clean and dry prior to instillation for topical therapy of external ear.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-life">Neuromuscular blockade</span> with muscular and <span class="speceff-life">respiratory paralysis</span>; hypersensitivity reactions. <span class="typehead">GI:</span> Mild laxative effect, diarrhea, nausea, vomiting; prolonged therapy: malabsorption-like syndrome including cyanocobalamin
      (vitamin B<sub>12</sub>) deficiency, low serum cholesterol. <span class="typehead">Urogenital:</span> <span class="speceff-life">Nephrotoxicity</span>. <span class="typehead">Special Senses:</span> <span class="speceff-life">Ototoxicity</span>. <span class="typehead">Skin:</span> <span class="speceff-common">Redness,</span> scaling, pruritus, dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease absorption of <b>cyanocobalamin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 3% absorbed from GI tract in adults; up to 10% absorbed in neonates. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Elimination:</span> 97% excreted unchanged in feces. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Perform audiometric studies twice weekly in patients with kidney or liver dysfunction receiving extended oral therapy.</li>
<li>Lab tests: Obtain baseline and daily urinalysis for albumin, casts, and cells; and BUN every other day. Also, serum drug levels
            (toxic levels reportedly range from 8 to 30 mcg/mL, although individual variations exist).
         </li>
<li>Monitor I&amp;O in patients receiving oral or parenteral therapy. Report oliguria or changes in I&amp;O ratio. Inadequate neomycin
            excretion results in high serum drug levels and risk of nephrotoxicity and ototoxicity.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Stop treatment and consult your physician if irritation occurs when you are using topical neomycin. Allergic dermatitis is
            common.
         </li>
<li>Report any unusual symptom related to ears or hearing (e.g., tinnitus, roaring sounds, loss of hearing acuity, dizziness).</li>
<li>Do not exceed prescribed dosage or duration of therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>